Basal insulin analogs and NPH insulin had similar rates of hypoglycemia hospital visits, glycemic control in type 2 diabetes
Researchers used data from Kaiser Permanente of Northern California to retrospectively assess patients with type 2 diabetes who initiated a long-acting insulin analog or NPH insulin between Jan. 1, 2006, and Sept. 30, 2015.
SGLT2 inhibitors, GLP-1 agonists associated with lower mortality compared to DPP-4 inhibitors, analysis finds
Glucagon-like peptide-1 (GLP-1) agonists were associated with a higher risk of adverse events than sodium-glucose cotransporter-2 (SGLT2) inhibitors or dipeptidyl peptidase 4 (DPP-4) inhibitors, according to the meta-analysis.
The results highlight the importance of psychosocial interventions for at-risk patients, they concluded.
Study finds potential early indicators of myocardial dysfunction in asymptomatic elderly patients with type 2 diabetes
Researchers examined asymptomatic patients 65 years of age and older with type 2 diabetes and preserved left ventricular ejection fraction to look for impaired global longitudinal strain, diastolic dysfunction, or left atrial enlargement.
Patients with diabetes who were taking any beta-blocker, a beta-1 selective beta-blocker, or a specific beta-blocker had significantly higher risk for all-cause mortality versus patients with diabetes who were not taking a beta-blocker.
After four years of follow-up, patients who had received intensive treatment during the trial had similar systolic blood pressure (BP) to those who had been on standard treatment but lower rates of cardiovascular (CV) events.
Patients with type 2 diabetes who had Roux-en-Y gastric bypass surgery maintained significant, although shrinking, improvements in HbA1c compared to those receiving lifestyle and medical management.
A cost-effectiveness analysis found that individualized control saved $13,547 per patient compared with uniform intensive control, primarily due to lower medication costs, and increased quality-adjusted life-years by 0.10.
Risk for major adverse cardiovascular events and all-cause mortality was higher when a sulfonylurea was added to metformin compared to other typical second- or third-line therapy options in a recent Danish study.
The retrospective study involved nearly 2.8 million male veterans 65 to 99 years of age, 32.3% with diabetes, who received primary care at Veterans Health Administration medical centers from 2000 to 2010.